[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100440033":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":33,"responsibleParty":117,"collaborators":20,"id":119,"slug":120,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":20,"eligibilityCriteria":125,"healthyVolunteers":121,"sex":126,"minAge":127,"maxAge":20,"enrollmentInfo":128,"targetDuration":20,"studyType":131,"phases":132,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"radiation","EXPERIMENTAL","Subjects will receive reduced dose radiation to radiographically progressive lesions identified on imaging (including asymptomatic bone metastases). The study uses a prespecified 2-stage design with early stopping after the first stage to evaluate whether treatment-failure rates are acceptably low relative to a historical benchmark.",[13],"Radiation: Palliative radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Palliative radiotherapy","Initial cohort (stage 1) of patients will receive 4Gy x 2. They will be re-evaluated at 2 and 6 months (+\u002F- 2 weeks). Accounting for anticipated survival times of these patients, we expect to have 12 evaluable patients from 20 enrolled patients. For stage 2 dose reduction will be explored across two palliative regimens, with timepoint for local failure adjusted accordingly.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Amy Xu, MD, PhD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","646-888-6863","xua@mskcc.org",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":20},"Daniel Gomez, MD","212-639-2087",[34,50,61,72,84,95,106],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Memorial Sloan Kettering Basking Ridge (All Protocol Activities)","RECRUITING","Basking Ridge","New Jersey","10065","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-74.54932,40.70621,{"lat":46,"lon":45},[49],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":20},{"facility":51,"status":36,"city":52,"state":38,"zip":53,"country":40,"countryCode":41,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Memorial Sloan Kettering Monmouth (All protocol activities)","Middletown","07748",{"type":43,"coordinates":55},[56,57],-74.11709,40.39428,{"lat":57,"lon":56},[60],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":20},{"facility":62,"status":36,"city":63,"state":38,"zip":64,"country":40,"countryCode":41,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Memorial Sloan Kettering Bergen (All protocol activities)","Montvale","07645",{"type":43,"coordinates":66},[67,68],-74.02292,41.04676,{"lat":68,"lon":67},[71],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":20},{"facility":73,"status":36,"city":74,"state":75,"zip":76,"country":40,"countryCode":41,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Memorial Sloan Kettering Commack (All protocol activities)","Commack","New York","11725",{"type":43,"coordinates":78},[79,80],-73.29289,40.84288,{"lat":80,"lon":79},[83],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":20},{"facility":85,"status":36,"city":86,"state":75,"zip":87,"country":40,"countryCode":41,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Memorial Sloan Kettering Westchester (All Protocol Activities)","Harrison","10604",{"type":43,"coordinates":89},[90,91],-73.71263,40.96899,{"lat":91,"lon":90},[94],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":20},{"facility":96,"status":36,"city":75,"state":75,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)",{"type":43,"coordinates":98},[99,100],-74.00597,40.71427,{"lat":100,"lon":99},[103,104,105],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":20},{"name":31,"role":27,"phone":32,"phoneExt":20,"email":20},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"facility":107,"status":36,"city":108,"state":75,"zip":109,"country":40,"countryCode":41,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Memorial Sloan Kettering Nassau (All protocol activities)","Uniondale","11553",{"type":43,"coordinates":111},[112,113],-73.59291,40.70038,{"lat":113,"lon":112},[116],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":20},{"type":118,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100440033","phase-2-a-study-of-reduced-dose-radiation-in-people-with-metastatic-tumors-with-a-genetic-change-100440033",false,"NCT05010031","A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change","Phase II Study to Examine Precision Radiation in Patients With Pathogenic Mutations in ATM","Inclusion Criteria:\n\n* Histologically confirmed malignancy with at least one metastatic lesion referred for palliative radiotherapy\n* Pathogenic mutation in ATM (somatic and germline allowed)\n* ECOG performance status 0-2\n* Age ≥ 18 years.\n* Able to provide informed consent.\n* Patients at reproductive potential must agree to practice an effective contraceptive method during radiation treatments.\n* Expected life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.\n* Serious medical co-morbidities precluding radiotherapy.\n* Pregnant or breast-feeding women.\n* Lesions excluded from de-escalation include regions in which the risk of local disease progression is unacceptably high, including CNS disease and cord compression, and areas in which re-irradiation would not be feasible, including spinal cord overlap.","ALL","18 Years",{"count":129,"type":130},45,"ESTIMATED","INTERVENTIONAL",[133],"PHASE2","This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.",[136],"Metastatic Cancer",[138,139,140,141],"Reduced-dose Radiation","Pathogenic Mutations","ATM (ataxia telangiectasia mutated)","21-310","2026-05-06",{"date":144,"type":145},"2026-05-11","ACTUAL",{"date":147,"type":145},"2021-08-11",{"date":149,"type":130},"2027-08",{"name":5,"class":6},7]